Why Is This Effective HSP90 Inhibitor Not Being Developed in HER2+ Breast Cancer?

被引：24

作者：

Arteaga, Carlos L. ^{[1
,2
]}

机构：

[1] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA

[2] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Breast Canc Res Program,Dept Canc Biol, Nashville, TN 37212 USA

来源：

CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 15期

关键词：

TRASTUZUMAB; COMBINATION;

D O I：

10.1158/1078-0432.CCR-11-1218

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibition of the HSP90 chaperone leads to degradation of the HER2 receptor. The HSP90 inhibitor tanespimycin in combination with trastuzumab is active in patients with HER2-overexpressing metastatic breast cancer. This combination is one of several HER2-targeted therapies that will significantly improve the outcome of patients with this subtype of breast cancer. Clin Cancer Res; 17(15); 4919-21. (C)2011 AACR.

引用

页码：4919 / 4921

页数：3

共 14 条

[1] New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available [J].

Abramson, Vandana ;

Arteaga, Carlos L. .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :952-958

[2]

Baselga J, 2011, CANCER RES, V70, pS3

[3] Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy [J].

Baselga, Jose ;

Gelmon, Karen A. ;

Verma, Shailendra ;

Wardley, Andrew ;

Conte, PierFranco ;

Miles, David ;

Bianchi, Giulia ;

Cortes, Javier ;

McNally, Virginia A. ;

Ross, Graham A. ;

Fumoleau, Pierre ;

Gianni, Luca .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1138-1144

[4] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].

Blackwell, Kimberly L. ;

Burstein, Harold J. ;

Storniolo, Anna Maria ;

Rugo, Hope ;

Sledge, George ;

Koehler, Maria ;

Ellis, Catherine ;

Casey, Michelle ;

Vukelja, Svetislava ;

Bischoff, Joachim ;

Baselga, Jose ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130

[5] Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth [J].

Chandarlapaty, S. ;

Scaltriti, M. ;

Angelini, P. ;

Ye, Q. ;

Guzman, M. ;

Hudis, C. A. ;

Norton, L. ;

Solit, D. B. ;

Arribas, J. ;

Baselga, J. ;

Rosen, N. .

ONCOGENE, 2010, 29 (03) :325-334

[6] Resistance to HER2-directed antibodies and tyrosine kinase inhibitors [J].

Garrett, Joan T. ;

Arteaga, Carlos L. .

CANCER BIOLOGY & THERAPY, 2011, 11 (09) :793-800

[7] Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib [J].

Leow, Ching Ching ;

Chesebrough, Jon ;

Coffman, Karen T. ;

Fazenbaker, Christine A. ;

Gooya, John ;

Weng, David ;

Coats, Steve ;

Jackson, Dowdy ;

Jallal, Bahija ;

Chang, Yong .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (08) :2131-2141

[8] Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I Dose-Escalation study [J].

Modi, Shanu ;

Stopeck, Alison T. ;

Gordon, Michael S. ;

Mendelson, David ;

Solit, David B. ;

Bagatell, Rochelle ;

Ma, Weining ;

Wheler, Jennifer ;

Rosen, Neal ;

Norton, Larry ;

Cropp, Gillian F. ;

Johnson, Robert G. ;

Hannah, Alison L. ;

Hudis, Clifford A. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (34) :5410-5417

[9] HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab [J].

Modi, Shanu ;

Stopeck, Alison ;

Linden, Hannah ;

Solit, David ;

Chandarlapaty, Sarat ;

Rosen, Neal ;

D'Andrea, Gabriella ;

Dickler, Maura ;

Moynahan, Mary E. ;

Sugarman, Steven ;

Ma, Weining ;

Patil, Sujata ;

Norton, Larry ;

Hannah, Alison L. ;

Hudis, Clifford .

CLINICAL CANCER RESEARCH, 2011, 17 (15) :5132-5139

[10] Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer [J].

Scaltriti, Maurizio ;

Serra, Violeta ;

Normant, Emmanuel ;

Guzman, Marta ;

Rodriguez, Olga ;

Lim, Alice R. ;

Slocum, Kelly L. ;

West, Kip A. ;

Rodriguez, Varenka ;

Prudkin, Ludmila ;

Jimenez, Jose ;

Aura, Claudia ;

Baselga, Jose .

MOLECULAR CANCER THERAPEUTICS, 2011, 10 (05) :817-824

← 1 2 →